×
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
NASDAQ:SPRO

Spero Therapeutics Earnings Date, Estimates & Call Transcripts (2022)

$0.94
-0.11 (-10.48%)
(As of 06/24/2022 04:00 PM ET)
Add
Compare
Today's Range
$0.94
$1.14
50-Day Range
$0.89
$5.95
52-Week Range
$0.85
$19.87
Volume
3.25 million shs
Average Volume
283,436 shs
Market Capitalization
$30.85 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$28.33

Earnings Summary

Upcoming
Earnings Date
Aug. 4Estimated
Actual EPS
(May. 16)
-$1.01 Missed By -$0.14
Consensus EPS
(May. 16)
-$0.87
Last Year's Q2 EPS
(5/6/2021)
-$0.66
Skip Charts & View Estimated and Actual Earnings Data

SPRO Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

SPRO Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Spero Therapeutics Earnings Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20221($0.56)($0.56)($0.56)
Q3 20221($0.25)($0.25)($0.25)

SPRO Earnings Date and Information

Spero Therapeutics last released its earnings results on May 16th, 2022. The reported ($1.01) earnings per share for the quarter, missing analysts' consensus estimates of ($0.87) by $0.14. The company had revenue of $2.07 million for the quarter, compared to the consensus estimate of $2.85 million. Spero Therapeutics has generated ($3.24) earnings per share over the last year (($3.24) diluted earnings per share). Earnings for Spero Therapeutics are expected to grow in the coming year, from ($2.88) to ($1.98) per share. Spero Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, August 4th, 2022 based off prior year's report dates.

Spero Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
8/4/2022
(Estimated)
        
5/16/2022Q1 2022($0.87)($1.01)($0.14)($1.01)$2.85 million$2.07 million    
3/31/2022Q4 2021($0.80)($0.90)($0.10)($0.90)$2.90 million$2.74 million    
11/10/20219/30/2021($0.66)($0.70)($0.04)($0.70)$3.00 million$3.06 million    
8/5/20216/30/2021($0.77)($0.63)+$0.14($0.63)$2.55 million$5.15 million  
5/6/20213/31/2021($0.61)($0.66)($0.05)($0.66)$2.71 million$7.30 million  
3/11/202112/31/2020($0.77)($0.68)+$0.09($0.68)$3.25 million$1.91 million  
11/5/20209/30/2020($0.91)($0.86)+$0.05($0.86)$2.28 million$4.00 million  
8/6/20206/30/2020($1.17)($0.85)+$0.32($0.85)$2.95 million$1.73 million  
5/8/20203/31/2020($1.35)($1.22)+$0.13($1.22)$3.36 million$1.70 million  
3/16/202012/31/2019($1.05)($1.32)($0.27)($1.32)$3.54 million$3.63 million
11/4/2019Q3($0.8470)($0.95)($0.1030)($0.95)$2.03 million$4.64 million
8/8/2019Q2 2019($0.64)($0.74)($0.10)($0.74)$6.95 million$2.16 million
5/9/2019Q1($0.7830)($0.29)+$0.4930($0.29)$1.25 million$7.72 million
3/14/2019Q4($0.7460)($0.60)+$0.1460($0.60)$0.84 million$1.69 million
11/8/2018Q3($0.64)($0.60)+$0.04($0.60)$0.66 million$0.66 million
8/9/2018Q2 2018($0.77)($0.69)+$0.08($0.69)$0.62 million$0.46 million
5/10/2018Q1 2018($1.1960)($0.74)+$0.4560($0.74)$0.20 million$1.15 million
4/2/2018Q4 2017($1.77)($1.59)+$0.18($1.59)$0.40 million$0.99 million
12/14/2017Q3 2017($2.43)($36.02)($33.59)($36.02)$0.20 million$0.60 million
8/6/2013Q213$0.01+$0.01$4.20 million$4.50 million
3/7/2013Q412($0.40)($0.40)$17.00 million$15.90 million












Spero Therapeutics Earnings - Frequently Asked Questions

When is Spero Therapeutics's earnings date?

Spero Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, August 4th, 2022 based off last year's report dates. Learn more on SPRO's earnings history.

Did Spero Therapeutics beat their earnings estimates last quarter?

In the previous quarter, Spero Therapeutics (NASDAQ:SPRO) missed the analysts' consensus estimate of ($0.87) by $0.14 with a reported earnings per share (EPS) of ($1.01). Learn more on analysts' earnings estimate vs. SPRO's actual earnings.

How can I listen to Spero Therapeutics's earnings conference call?

The conference call for Spero Therapeutics's latest earnings report can be listened to online. Listen to Conference Call

How can I read Spero Therapeutics's conference call transcript?

The conference call transcript for Spero Therapeutics's latest earnings report can be read online. Read Transcript

How much revenue does Spero Therapeutics generate each year?

Spero Therapeutics (NASDAQ:SPRO) has a recorded annual revenue of $18.26 million.

How much profit does Spero Therapeutics generate each year?

Spero Therapeutics (NASDAQ:SPRO) has a recorded net income of -$89.76 million. SPRO has generated -$3.24 earnings per share over the last four quarters.

What is Spero Therapeutics's EPS forecast for next year?

Spero Therapeutics's earnings are expected to grow from ($2.88) per share to ($1.98) per share in the next year.

This page (NASDAQ:SPRO) was last updated on 6/26/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.